23andMe, a popular direct-to-consumer genetic testing company, made headlines after its CEO pledged to help reunite the more than 2,300 children separated from their parents at the U.S.’s southern ...

The story sounds like a modern fairy tale gone sideways: a Massachusetts woman takes a DNA test, finds two half-sisters she ...

Tarrytown-based Regeneron would acquire 23andMe for $256 million under the deal that is pending approval by bankruptcy court and regulators. New York-based biotech giant Regeneron Pharmaceuticals ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals’ offer for the DNA-testing company in a bankruptcy auction.

23andMe, which sold saliva collection kits to consumers wanting insight into their genetic background, filed for bankruptcy in March 2025. The company has now agreed to sell its data bank to Regeneron ...

Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year. The DNA testing company has faced major ...

A bankruptcy judge approved a US class settlement, and related attorneys’ fees, with former customers of DNA testing firm ...

New York and other states filed a lawsuit seeking to block 23andMe, the bankrupt genetic testing firm, from selling millions of Americans' genetic data to the highest bidder. A total of 28 state ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s privacy ...

Genetic testing company 23andMe laid off 100 employees on Jan. 23 due to decreasing sales of its direct-to-consumer DNA test kits, CNBC reports. The layoffs, which affect about 14 percent of the ...

Direct-to-consumer genetic testing now a booming industry—and it’s easy to see why. A simple swap of the inside of your mouth can provide you with insights into your ethnicity, health, and long-lost ...

New York-based biotech giant Regeneron Pharmaceuticals announced May 19 its plan to purchase the bankrupt genetic testing firm 23andMe in a $256 million deal that could include millions of Americans' ...